Core Viewpoint - Rosen Law Firm is reminding investors of Kyverna Therapeutics, Inc. about the upcoming lead plaintiff deadline for a class action lawsuit related to the company's IPO on February 8, 2024 [1][2]. Group 1: Class Action Details - Investors who purchased Kyverna common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 7, 2025 [2]. - The lawsuit claims that Kyverna's IPO registration statement and prospectus contained misstatements and omissions regarding the clinical trial results of its lead product candidate, KYV-101 [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3]. Group 3: Case Specifics - The lawsuit alleges that Kyverna misrepresented patient "improvement" indicators while failing to disclose adverse data known at the time of the IPO, leading to artificially inflated stock prices [4]. - When the true details about the clinical trials became public, investors reportedly suffered damages [4].
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit